Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment; Drug · Radiation · Other + 1 more
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Precancerous Condition
Interventions: HspE7; Biological
Lead sponsor: Dana-Farber/Brigham and Women's Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Verruca Vulgaris, Common Warts
Interventions: ingenol mebutate 0.05% gel; Drug
Lead sponsor: Neal D. Bhatia, MD; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cervical Cancer, Human Papillomavirus Infection
Interventions: Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 2,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Interventions: Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Las Cruces, New Mexico • El Paso, Texas

Conditions: Papillomavirus Infections
Interventions: VGX-3100; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
Interventions: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: EBV, HSV, VZV, HPV, CMV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 5
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 2 more

Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more

Conditions: Infections, Papillomavirus
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer, Vaginal Cancer, Vulvar Cancer, Anal Cancer, Penile Cancer
Interventions: WoW and BNI; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 9 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer, HPV Infection
Interventions: Qualitative Interview, Virtual Visit Standard Instructions, Virtual Visit Standard Instructions + In-Person Registration Navigation; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Human Papillomavirus Infection
Interventions: Not listed
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 3
States / cities: Lake Success, New York • Burlington, North Carolina • Cleveland, Ohio

Conditions: Condylomata Acuminata
Interventions: East Indian Sandalwood Oil Cream; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Common Wart
Interventions: A-101; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 46
States / cities: Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more

Conditions: Human Papillomavirus Infection
Interventions: Not listed
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Genital Warts
Interventions: Imiquimod, 3.75% imiquimod cream, placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions: OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 50 Years to 64 Years
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Human Papillomavirus Infection
Interventions: Communication Intervention, Communication Skills Training, Healthcare Activity, Survey Administration; Other · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Interventions: Best Practice, Communication Intervention, Electronic Health Record Review, HPV Self-Collection, Standard Follow-Up Care; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 63 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Prospective Evaluation of Self-Testing to Increase Screening

Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Prevalence of Human Papillomavirus in Men Living in the Northern Plains

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study

Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening